BTK and B-cell chronic lymphocytic leukemia: In the cohort of CLL, 8 individuals (53.4%) were receiving active treatment: 4 of them with Bruton Tyrosine Kinase (BTK) inhibitors, 3 with Rituximab and Venetoclax and 1 with Rituximab and Idelalisib; whereas 7 individuals (46.6%) were on a Watch and Wait follow-up.